Published in J Psychiatr Res on November 10, 1999
Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol (2005) 8.49
Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry (2011) 3.33
Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3). Trends Immunol (2009) 1.96
Cascading effects of stressors and inflammatory immune system activation: implications for major depressive disorder. J Psychiatry Neurosci (2009) 1.58
Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients. J Clin Oncol (2008) 1.56
Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology (Berl) (2003) 1.46
The evolutionary significance of depression in Pathogen Host Defense (PATHOS-D). Mol Psychiatry (2012) 1.41
[Psychotropic drugs and diabetes]. Wien Med Wochenschr (2011) 1.40
Pro- and anti-inflammatory cytokine balance in major depression: effect of sertraline therapy. Clin Dev Immunol (2007) 1.34
Cytokine-induced depression during IFN-alpha treatment: the role of IL-6 and sleep quality. Brain Behav Immun (2009) 1.31
Immune System and Schizophrenia. Curr Immunol Rev (2010) 1.18
Increased plasma levels of soluble TNF receptor I in patients with bipolar disorder. Eur Arch Psychiatry Clin Neurosci (2010) 1.06
A psychoneuroimmunological perspective to Emil Kraepelins dichotomy: schizophrenia and major depression as inflammatory CNS disorders. Eur Arch Psychiatry Clin Neurosci (2008) 1.01
A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry (2016) 0.99
Serum IL-1beta, sIL-2R, IL-6, IL-8 and TNF-alpha in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment. Mediators Inflamm (2001) 0.98
Effects of antipsychotics on the inflammatory response system of patients with schizophrenia in peripheral blood mononuclear cell cultures. Clin Psychopharmacol Neurosci (2013) 0.96
Pharmacogenetics of antipsychotic-induced weight gain. Psychopharmacology (Berl) (2004) 0.92
The impact of neuroimmune dysregulation on neuroprotection and neurotoxicity in psychiatric disorders--relation to drug treatment. Dialogues Clin Neurosci (2009) 0.90
Plasma levels of leptin and endogenous immune modulators during treatment with carbamazepine or lithium. Psychopharmacology (Berl) (2004) 0.87
Effect of selective serotonin reuptake inhibitors and immunomodulator on cytokines levels: an alternative therapy for patients with major depressive disorder. Clin Dev Immunol (2013) 0.85
Moderating effects of moderate-intensity physical activity in the relationship between depressive symptoms and interleukin-6 in primary care patients. Psychosom Med (2011) 0.85
Impaired neuroendocrine and immune response to acute stress in medication-naive patients with a first episode of psychosis. Schizophr Bull (2010) 0.85
Plasma Levels of IL-23 and IL-17 before and after Antidepressant Treatment in Patients with Major Depressive Disorder. Psychiatry Investig (2013) 0.84
Chronic variable stress induces oxidative stress and decreases butyrylcholinesterase activity in blood of rats. J Neural Transm (Vienna) (2010) 0.84
Towards an Immunophenotype of Schizophrenia: Progress, Potential Mechanisms, and Future Directions. Neuropsychopharmacology (2016) 0.83
The TNF-alpha system: functional aspects in depression, narcolepsy and psychopharmacology. Curr Neuropharmacol (2008) 0.82
Increased serum interleukin-1beta and interleukin-6 in elderly, chronic schizophrenic patients on stable antipsychotic medication. Neuropsychiatr Dis Treat (2005) 0.82
Cytokine profile in patients undergoing minimally invasive surgery with balanced anesthesia. Inflammation (2012) 0.81
[Atypical antipsychotics and metabolic syndrome]. Wien Med Wochenschr (2007) 0.80
Glia in the cytokine-mediated onset of depression: fine tuning the immune response. Front Cell Neurosci (2015) 0.79
Regulation of interleukin-6 and leptin in schizophrenia patients: a preliminary analysis. Clin Psychopharmacol Neurosci (2014) 0.79
Genome-Wide Association Studies Suggest Limited Immune Gene Enrichment in Schizophrenia Compared to 5 Autoimmune Diseases. Schizophr Bull (2016) 0.79
Effects of risperidone on cytokine profile in drug-naïve first-episode psychosis. Int J Neuropsychopharmacol (2014) 0.78
Plasma concentrations of soluble cytokine receptors in euthymic bipolar patients with and without subsyndromal symptoms. BMC Psychiatry (2012) 0.78
Recent topics related to testosterone deficiency syndrome in Japan. Asian J Androl (2011) 0.76
Increased Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels in Plasma of Suicide Attempters. PLoS One (2015) 0.76
Comparison of inflammatory cytokine profiles in plasma of patients undergoing otorhinological surgery with propofol or isoflurane anesthesia. Inflamm Res (2013) 0.76
Utilization of never-medicated bipolar disorder patients towards development and validation of a peripheral biomarker profile. PLoS One (2013) 0.76
Simultaneous measurement of 23 plasma cytokines in late-life depression. Neurol Sci (2009) 0.76
Cytokines, neurophysiology, neuropsychology, and psychiatric symptoms. Dialogues Clin Neurosci (2003) 0.76
Cytokines in Schizophrenia: Hope or Hype? Indian J Psychol Med (2016) 0.75
Inflammation in Schizophrenia: Cytokine Levels and Their Relationships to Demographic and Clinical Variables. Am J Geriatr Psychiatry (2016) 0.75
Serial mitogen-stimulated cytokine production from continuously ill patients with schizophrenia. Neuropsychopharmacology (2010) 0.75
The reduction of CSF tumor necrosis factor alpha levels in schizophrenia: no correlations with psychopathology and coincident metabolic characteristics. Neuropsychiatr Dis Treat (2016) 0.75
Differential expression of the inflammation marker IL12p40 in the at-risk mental state for psychosis: a predictor of transition to psychotic disorder? BMC Psychiatry (2016) 0.75
Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry (2001) 4.70
Brain activation and hypothalamic functional connectivity during human non-rapid eye movement sleep: an EEG/fMRI study. Brain (2005) 2.07
Circulatory and respiratory complications of carbon dioxide insufflation. Dig Surg (2004) 2.06
Increased body-mass index in patients with narcolepsy. Lancet (2000) 1.78
T cells specific for the myelin oligodendrocyte glycoprotein mediate an unusual autoimmune inflammatory response in the central nervous system. Eur J Immunol (1993) 1.74
Effects of intranasal hypocretin-1 (orexin A) on sleep in narcolepsy with cataplexy. Sleep Med (2011) 1.50
Simian immunodeficiency virus variants with differential T-cell and macrophage tropism use CCR5 and an unidentified cofactor expressed in CEMx174 cells for efficient entry. J Virol (1997) 1.49
[Findings in a high-risk group following asbestos exposure. Benefit of ENT examinations in patients with long-term exposure to asbestos]. HNO (2002) 1.39
Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. Mol Psychiatry (2006) 1.38
Experimental autoimmune panencephalitis and uveoretinitis transferred to the Lewis rat by T lymphocytes specific for the S100 beta molecule, a calcium binding protein of astroglia. J Exp Med (1994) 1.33
Sleep and periodic leg movement patterns in drug-free patients with Parkinson's disease and multiple system atrophy. Sleep (2000) 1.30
Illness, cytokines, and depression. Ann N Y Acad Sci (2000) 1.27
Dose-dependent effects of endotoxin on human sleep. Am J Physiol Regul Integr Comp Physiol (2000) 1.26
Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1. Clin Ther (1996) 1.21
Low leptin levels but normal body mass indices in patients with depression or schizophrenia. Neuroendocrinology (2001) 1.19
Normal plasma levels of orexin A (hypocretin-1) in narcoleptic patients. Neurology (2001) 1.16
[Prevention, diagnosis, therapy, and follow-up of lung cancer]. Pneumologie (2010) 1.14
EFNS guidelines on management of narcolepsy. Eur J Neurol (2006) 1.13
Depression, comorbidities and the TNF-alpha system. Eur Psychiatry (2008) 1.12
Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine. Pharmacopsychiatry (2002) 1.10
Effects of clozapine on in vitro immune parameters: a longitudinal study in clozapine-treated schizophrenic patients. Neuropsychopharmacology (1998) 1.07
Altered cytokine production and accessory cell function after HIV-1 infection. J Immunol (1996) 1.06
Prevention, diagnosis, therapy, and follow-up of lung cancer: interdisciplinary guideline of the German Respiratory Society and the German Cancer Society. Pneumologie (2010) 1.06
Expression of ryanodine receptor type 3 and TRP channels in endothelial cells: comparison of in situ and cultured human endothelial cells. Cardiovasc Res (2001) 1.05
Impaired hyperpolarization in regenerated endothelium after balloon catheter injury. Circ Res (2001) 1.04
Effects of antipsychotic drugs on cytokine networks. J Psychiatr Res (2001) 1.02
L-dopa therapy of uremic and idiopathic restless legs syndrome: a double-blind, crossover trial. Sleep (1995) 1.01
Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry (1999) 1.01
Pneumoconiosis and emphysema in construction workers: results of HRCT and lung function findings. Occup Environ Med (2011) 0.98
Sleep in schizophrenia: a polysomnographic study on drug-naive patients. Neuropsychopharmacology (1997) 0.98
Periodic leg movements in sleep and restless legs syndrome probably caused by olanzapine. J Clin Psychopharmacol (1999) 0.97
Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J Clin Psychopharmacol (1996) 0.96
Nocturnal plasma levels of cytokines in healthy men. Eur Arch Psychiatry Clin Neurosci (1992) 0.96
Reduced leptin levels in human narcolepsy. Neuroendocrinology (2000) 0.95
Effects of antidepressants on weight and on the plasma levels of leptin, TNF-alpha and soluble TNF receptors: A longitudinal study in patients treated with amitriptyline or paroxetine. Neuropsychopharmacology (2000) 0.94
[The role of 3-D imaging and computer-based postprocessing for surgery of the liver and pancreas]. Rofo (2005) 0.93
Research and development of biosensors. A review. Analyst (1989) 0.93
Chronic insomnia: clinical and research challenges--an agenda. Pharmacopsychiatry (2010) 0.92
[Health effects of particulate matter exposure: current scientific knowledge]. Pneumologie (2009) 0.91
[Prevention, diagnosis, therapy, and follow-up of lung cancer. Interdisciplinary guideline of the German Respiratory Society and the German Cancer Society--abridged version]. Pneumologie (2011) 0.91
Visual hallucinations and psychotic symptoms during treatment with selective serotonin reuptake inhibitors: is the sigma receptor involved? J Clin Psychopharmacol (2000) 0.90
Combining high-field EPR with site-directed spin labeling reveals unique information on proteins in action. Magn Reson Chem (2005) 0.90
Automatic detection of periodic leg movements (PLM) J Sleep Res (1996) 0.90
Volatile anesthetics differentially affect immunostimulated expression of inducible nitric oxide synthase: role of intracellular calcium. Anesthesiology (2000) 0.90
In vitro cytokine secretion in individuals with schizophrenia: results, confounding factors, and implications for further research. Brain Behav Immun (2001) 0.89
Comminuted fractures of the proximal ulna--Preliminary results with an anatomically preshaped locking compression plate (LCP) system. Injury (2010) 0.88
Ghrelin and eating disturbances in psychiatric disorders. Neuropsychobiology (2008) 0.88
Mediators of inflammation and their interaction with sleep: relevance for chronic fatigue syndrome and related conditions. Ann N Y Acad Sci (2001) 0.88
Recombinant human erythropoietin delays loss of gray matter in chronic schizophrenia. Mol Psychiatry (2010) 0.87
Endotoxin-induced changes in sleep and sleepiness during the day. Psychoneuroendocrinology (1998) 0.87
Effect of coadministration of clozapine and fluvoxamine versus clozapine monotherapy on blood cell counts, plasma levels of cytokines and body weight. Psychopharmacology (Berl) (2000) 0.87
Levels of 8-hydroxy-2'-deoxyguanosine in DNA of white blood cells from workers highly exposed to asbestos in Germany. Mutat Res (2000) 0.87
The Baumann procedure to correct equinus gait in children with diplegic cerebral palsy: long-term results. J Bone Joint Surg Br (2012) 0.86
Effects of granulocyte colony-stimulating factor on night sleep in humans. Am J Physiol (1999) 0.86
Dose-dependence of bacterial lipopolysaccharide (LPS) effects on peak response and time course of the immune-endocrine host response in humans. Inflamm Res (1999) 0.85
Granulocyte colony-stimulating factor plasma levels during clozapine- and olanzapine-induced granulocytopenia. Acta Psychiatr Scand (2000) 0.85
In vivo and in vitro immune variables in patients with narcolepsy and HLA-DR2 matched controls. Neurology (1998) 0.85
Effects of an intravenous catheter on the local production of cytokines and soluble cytokine receptors in healthy men. Cytokine (2000) 0.84
Fabrication of silicon nanowire arrays by near-field laser ablation and metal-assisted chemical etching. Nanotechnology (2016) 0.84
Endotoxin-induced changes in food consumption in healthy volunteers are associated with TNF-alpha and IL-6 secretion. Psychoneuroendocrinology (2002) 0.84
Analysis of quality and feasibility of an objective structured clinical examination (OSCE) in preclinical dental education. Eur J Dent Educ (2011) 0.84
Effects of sleep on endotoxin-induced host responses in healthy men. Psychosom Med (2001) 0.84
A method for the quantification of biomarkers of exposure to acrylonitrile and 1,3-butadiene in human urine by column-switching liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem (2008) 0.84
A comparison of the effects of clozapine and olanzapine on the EEG in patients with schizophrenia. Pharmacopsychiatry (2000) 0.83